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Abstract
Background: The measurement of health benefits is a key issue in health economic evaluations. There is very scarce 
empirical literature exploring the differences of using quality-adjusted life years (QALYs) or disability-adjusted life years 
(DALYs) as benefit metrics and their potential impact in decision-making.
Methods: Two previously published models delivering outputs in QALYs, were adapted to estimate DALYs: a Markov 
model for human papilloma virus (HPV) vaccination, and a pneumococcal vaccination deterministic model (PNEUMO). 
Argentina, Chile, and the United Kingdom studies were used, where local EQ-5D social value weights were available to 
provide local QALY weights. A primary study with descriptive vignettes was done (n = 73) to obtain EQ-5D data for all 
health states included in both models. Several scenario analyses were carried-out to evaluate the relative importance of 
using different metrics (DALYS or QALYs) to estimate health benefits on these economic evaluations.
Results: QALY gains were larger than DALYs avoided in all countries for HPV, leading to more favorable decisions 
using the former. With discounting and age-weighting – scenario with greatest differences in all countries – incremental 
DALYs avoided represented the 75%, 68%, and 43% of the QALYs gained in Argentina, Chile, and United Kingdom 
respectively. Differences using QALYs or DALYs were less consistent and sometimes in the opposite direction for 
PNEUMO. These differences, similar to other widely used assumptions, could directly influence decision-making using 
usual gross domestic products (GDPs) per capita per DALY or QALY thresholds.
Conclusion: We did not find evidence that contradicts current practice of many researchers and decision-makers of 
using QALYs or DALYs interchangeably. Differences attributed to the choice of metric could influence final decisions, 
but similarly to other frequently used assumptions.
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Implications for policy makers
• Quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs) are usually used interchangeably in economic evaluations of health 
technologies.
• This paper shows that the magnitude of health benefit estimated through QALYs or DALYs could be significantly different and potentially alter 
the study conclusions.
• The magnitude of the uncertainty associated to the choice of metric was not greater to other common sources of uncertainty in economic 
evaluations (ie, discounting, parameter or structural uncertainty).
Implications for the public
In this paper we show that the choice of the measure of health benefit (Quality-adjusted life years [QALYs] or disability-adjusted life years [DALYs]) 
can potentially alter the results and conclusions of an economic evaluation to determine the cost-effectiveness of a health technology. This finding, 
together with other sources of uncertainty should be taken into account when designing, performing or reporting this type of studies.
Key Messages 
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Background
The measurement of health benefits is a key issue in health 
economic evaluations and health policy, however the choice 
of the metric of measurement is not uniformly acknowledged. 
Traditional cost-benefit measurement, for example, requires 
that both costs and consequences are measured in terms of 
monetary value. Whilst the measurement of costs is relatively 
straightforward, there are differing opinions as to the 
mechanism for assigning a monetary value to health benefits – 
and indeed whether such an assignment is acceptable. For the 
measurement of health benefit to have the greatest potential 
use in order to inform allocative efficiency decisions, it needs 
to be based on a generic system so that gains/losses can be 
compared across the widest possible range of therapeutic 
interventions. In this context, measures of health or health 
assessment, and specially combined metrics that incorporate 
life expectancy and quality of life or disability have been widely 
adopted. Two main different generic paradigms have been 
proposed for setting healthcare priorities: quality-adjusted 
life years (QALYs) based on the effect of interventions, and 
disability-adjusted life years (DALYs) based on the burden 
of disease in a population. These formal paradigms recall 
the assumptions implicitly made in the everyday delivering 
of, and hence rationing access to, healthcare. Nowadays, 
these two paradigms have emerged as the main contenders 
in informing national agencies and global decision-makers, 
although not without controversy and with the availability 
of other alternative potential metrics.1 Due to the scarcity 
of empirical comparisons of economic evaluations using 
QALYs or DALYs, we undertook a comparative exploratory 
exercise based on recent economic evaluations our group 
was involved in. In order to have a broad scope, we included 
economic evaluations based on two models evaluating two 
vaccines (human papilloma virus - HPV - and conjugated 
pneumococcal) with researchers from the collaborative team.
Methods
Two preventive models were selected in order to empirically 
address the effect of using DALY and QALY-based methods 
to compute health benefits in economic evaluations: an 
HPV cohort based Markov vaccination model,2 and a 
pneumococcal compartmental vaccination model.3 Both 
models were developed in Microsoft Excel®, and originally 
used only QALYs as the primary health benefit measure, 
incorporating QALY weights from international sources. 
These models have been applied in different countries around 
the world.2,4,5 For the present study, we analyzed and compared 
model adaptations from Argentina, Chile, and the United 
Kingdom because EQ-5D social value weights were available 
for these countries.6-8 This allowed to explore the impact 
of country-specific utility weights for QALYs on results 
across countries. In addition, models were reprogrammed 
in order to estimate both components required to estimate 
DALYs: years of life with disability (YLD) produced by the 
same conditions, as well as the years of life lost (YLLs) by 
premature death. See more details about model description 
in Appendix 1.
Human Papilloma Virus Vaccination Model
The HPV vaccination model is a Markov model reflecting 
the natural history of oncogenic HPV infection, through 12 
different health states. The model follows a cohort of 11-year 
old girls over lifetime under two different strategies: current 
Pap screening program or current Pap screening program 
plus bivalent HPV vaccination at 12 years old. General 
description of the model and results for Argentina, Chile, and 
United Kingdom has been published elsewhere.2,5 Briefly, the 
model considers the epidemiology of HPV, the characteristics 
of the screening program, the treatment guidelines and the 
specific costs for each country. In order to model the natural 
history of oncogenic HPV infection and cancer development, 
incidences of HPV infection for each country were modeled 
from local prevalence studies. For all other state-transition 
probabilities, as local studies were not available, data from 
the United Kingdom was used for all three countries. Finally, 
models were calibrated to country specific vital statistics 
in order to reproduce local epidemiology of HPV related 
diseases. 
Pneumococcal Vaccination Model
The pneumococcal vaccination model is static, deterministic 
and age-compartmental.3 It considers the occurrence of four 
pneumococcal related diseases (meningitis, bacteraemia, 
pneumonia and acute otitis media) in a calendar year, across 
all age cohorts. Additionally, present value of future costs 
and disutilities related to events’ sequelae that start in that 
year are incorporated. The model is able to address the cost-
effectiveness of the introduction of different pneumococcal 
vaccines (Synflorix® or Prevnar® as compared to no 
vaccination) in local vaccination programs. In the present 
study we reprogrammed the model using Synflorix® as an 
example.
Estimating Quality-Adjusted Life Years
For each health state in both models, descriptive vignettes 
based on the EQ-5D-3L instrument were administered to a 
convenience sample of 73 healthy people in Argentina who 
had completed their high school studies, in order to gather 
descriptive health state data. More details of this sub-study 
were previously published.9 Finally, as local social values are 
available in the three countries analyzed,6-8 these country 
specific EQ-5D weights were used in order to map the same 
mix of descriptive health states for each health state into local 
QALY weights. 
Pneumococcal vaccination model also contemplates including 
normative utilities by age, that is, the mean utility of spending 
a year alive for the general population. Normative utilities 
were obtained from local valuation studies and population 
surveys of Argentina,6,10 Chile (V. Zarate V, P. Kind, personal 
communication, 2009)8,11 and the United Kingdom.11 In a 
scenario analysis we explored the impact of using QALYs 
estimated without normative utilities.
Calculating Disability-Adjusted Life Years
By default, both models estimate QALYs, so they were 
reprogrammed in order to include DALYs. To calculate 
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DALYs we employed individual equations for YLL and YLD 
published elsewhere.12-15 A population figure was obtained 
by multiplying each individual result by the incident cases, 
deaths or disability cases that were estimated by the models. 
Additional details about the DALY calculations can be found 
in Appendix 2.
Standard expectation of life for YLL calculations were extracted 
from life-table West Level 26.14 In an alternative scenario 
we used local life tables for each country. Disability weights 
were obtained from the 2004 update of the Global Burden of 
Disease study12,16 for all the pneumococcal vaccination model 
states. Disability weights unavailable for the HPV vaccination 
model (ie, all states except cancer related states), were 
obtained following the methodology described in a Dutch 
study.15 This study transformed EQ-5D descriptive data to a 
disability weight using a multiple regression equation. There 
was no need to estimate independently disease duration for 
estimating DALYs (ie, with DISMOD model) as they were 
obtained by the Markov models. 
Models Analysis
For the analysis, epidemiological parameters (such as 
incidence, acute mortality, or transition between different 
states) were kept as in the original published studies.2,3 The 
main difference in the base-case analysis from the original 
studies were: (1) that specific EQ-5D values using country 
specific value sets for health state were included; and (2) 
models have been reprogrammed to estimate DALYs 
alongside QALYs based on GBD weights as described. For 
both models we selected to report the analysis of the QALY 
vs. DALY using a denominator of 100 000 subjects, though 
this was not always the denominator in the published studies.
First, we estimated the incremental benefit associated to each 
of the interventions, using both QALYs gained and DALYs 
avoided. Four scenarios to compare QALY with DALY results 
were estimated: with and without a 3.5% annual discount 
rate for both QALYs and DALYs, and with and without 
age weighting for DALYs. Second, in order to compare the 
relative difference between QALYs and DALYs in each 
scenario, a DALYs avoided/QALYs gained percentage ratio 
was estimated. So, a percentage ratio of 100% means that 
benefits were exactly the same with both metrics, a percentage 
ratio greater than 100% means that DALYs avoided were 
greater than QALYs gained, and a percentage ratio lower 
than 100% means that QALYs gained were greater. Third, we 
estimated the potential impact on decision-making of using 
these different metrics. In order to achieve this, for each 
model and country, we estimated the maximum incremental 
costs per person receiving the intervention that would make 
the strategy be deemed very cost-effective or cost-effective. 
Though now controversial, for illustration on how a specific 
decision rule, using either QALYs or DALYs, could impact 
the study conclusions, we used the willingness to pay 
thresholds according to gross domestic product (GDP) per 
capita proposed by the World Health Organization (WHO).17 
According to this guidance, an intervention is very cost-
effective if its incremental cost-effectiveness ratio (ICER) is 
less or equal 1 GDP per capita per DALY; cost-effective if it 
ranges from >1 and < equal 3; and not cost-effective if it is 
greater than three GDPs per capita per DALY. Though this 
rule was originally designed for DALYs, more commonly used 
in lower and middle income country settings, it is often used 
interchangeably for QALYs, used both in developed countries 
as well as in less developed ones. GDPs for each country 
were obtained from the International Monetary Fund and 
expressed in International Dollars 2013,18 which represent a 
Purchasing Power adjusted value. 
Finally, in order to explore some potential factors that may 
influence these differences, we explored the impact of some 
model assumptions on several additional scenario analyses 
(sensitivity analysis). We explored replacing each countries 
EQ-5D based QALY weights by “1-DALY’s disability weight”; 
we varied influential parameters in the parent economic 
evaluation in the case of pneumococcal vaccine  – those related 
to acute otitis media; used of local life expectancies to estimate 
DALYs; and incorporated normative (general population) 
utilities to estimate QALYs in the HPV vaccination model 
which were not incorporated in the base-case analyses; and 
also tested a scenario where the demographic characteristics 
of the three countries population was standardized in order 
to explore whether demographic differences had an impact 
in the QALY vs. DALY differences. The alternative scenario 
results are not the focus of the main paper; interested readers 
can see Appendix 3. 
Results 
Human Papilloma Virus Vaccination Model
Table 1 shows QALYs gained and DALYs avoided comparing 
HPV vaccination against no intervention in the four base-case 
scenarios (with and without discounting of both QALYs and 
DALYs; and with and without DALYs age-weighting). In most 
Table 1. Incremental Healthy Years (QALYs Gained or DALYs Avoided) 
Comparing HPV Vaccination Against no Vaccination (per 100 000 Women)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Without Discount, With Age Weighting on DALYs
Argentina 13 750.93 11 377.14 82.74%
Chile 10 034.62 6969.72 69.46%
UK 9189.99 5484.66 59.68%
3.5% Discount Rate With Age Weighting on DALYs
Argentina 2458.03 1843.39 74.99%
Chile 1669.11 1142.28 68.44%
UK 1858.57 796.37 42.85%
Without Discount, Without Age Weighting on DALYs
Argentina 13 750.93 14 965.23 108.83%
Chile 10 034.62 9321.46 92.89%
UK 9189.99 7431.34 80.86%
3.5% Discount Rate Without Age Weighting on DALYs
Argentina 2 458.03 2 211.29 89.96%
Chile 1 669.11 1 357.41 81.33%
UK 1 858.57 1 025.83 55.19%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year.
a Main scenarios for basal analysis (with and without discounting; with or 
without DALY age-weighting). 
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of the analyses, QALYs gains were larger than DALYs avoided, 
which would lead to more favorable decisions regarding cost-
effectiveness if QALYs were used as the benefit metric.
Differences were larger in the United Kingdom and smaller in 
Argentina. The incorporation of discounting and DALYs age 
weighting affected most markedly the estimation of DALYs, 
increasing the difference with QALYs in all countries, where 
incremental DALYs avoided represented 75%, 68%, and 43% 
of the QALYs gained in Argentina, Chile, and the United 
Kingdom respectively. On the other hand, differences were 
smaller, and within +/- 20% range when no discounting nor 
age weighting were used. 
In order to depict how these differences in the magnitude 
of benefit estimation if using QALYs or DALYs could have 
influenced decision-making, we show in Figure 1 how a new 
intervention with a particular incremental cost would change 
the decision based on QALYs or DALYs, and using the 1 and 
3 GDP thresholds for QALYs or DALYs in the four scenarios 
and the three countries.
For instance, in the United Kingdom (with discounting and 
no age weights) as QALY estimation results in more benefits, 
an incremental cost per vaccinated person up to $2036 would 
be considered cost-effective using a 3 GDP threshold; while 
the same intervention would be considered cost-effective 
using DALYs only if the incremental cost per person is $1124 
or less. This is another way of reflecting the 55% percentage 
ratio shown in Table 1 for this scenario. In this case example, 
decisions were more likely to agree if discounting and age 
weighting are used, but this can depend on the value of the 
final incremental cost of the study, and thus the incremental 
cost-effectiveness ratio for each country in relation to the 
decision threshold.
Pneumococcal Vaccination Model
Differences in incremental benefits using QALYs gained or 
DALYs saved show a different picture than in the HPV case 
study. In this case QALYs and DALYs gains were similar, and 
sometimes greater using DALYs, which would either not 
affect the decision or lead to more favourable decisions if 
DALYs were used as the benefit metric. 
Table 2 shows incremental benefits in each country and 
scenario. Differences usually decreased when using 
discounting and no age weighting. Unlike the HPV case, 
in which differences were consistently larger in the United 
Kingdom and smaller in Argentina, there was no uniform 
pattern for all scenarios. Differences were larger in Argentina 
in those scenarios with age weighting, and larger in the United 
Kingdom in those scenarios without age weighting.
As an example, in the United Kingdom, QALY-DALY 
differences showed by the DALY/QALY percentage ratio 
were lower when age weighting was used in order to estimate 
DALYs avoided (difference ranged from -0.45% -percentage 
ratio 99.55%- [with discount and age weighting] to +34.85% 
[with age weighting and no discount]). 
The influence of these differences between QALYs and DALYs 
in decision-making was smaller than in the HPV case and is 
shown in Figure 2.
Similarly to Figure 1, Figure 2 depicts the mean incremental 
cost of the strategy at which the decision would change. 
Differences were rather small (within 5%) in the scenario 
Figure 1. HPV Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or DALYs for 
Argentina, Chile and the United Kingdom. Main scenarios for basal analysis (with and without discounting; with or without DALY age-weighting). 
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
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with discounting and age weighting in all countries. In other 
scenarios, they were within +/-20%, except in the United 
Kingdom, where in the scenarios without age weighting 
Figure 2. Pneumococcal Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 Or 3 GDP Thresholds Change Using QALYs 
or DALYs for Argentina, Chile and United Kingdom. Main scenarios for basal analysis (with and without discounting; with or without DALY age-
weighting). 
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
 
Table 2. Incremental Healthy Years (QALYs Gained or DALYs Avoided) 
Comparing Conjugated Pneumococcal Vaccination Against no Vaccination 
(Per 100 000 Subjects)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Conjugated Pneumococcal Vaccine vs. no Vaccination
Without Discount, With Age Weighting on DALYs
Argentina 16.50 20.27 122.85%
Chile 35.84 40.10 111.88%
UK 21.47 22.29 103.83%
3.5%  Discount Rate With Age Weighting on DALYs
Argentina 6.95 7.25 104.38%
Chile 15.75 15.72 99.79%
UK 13.20 13.14 99.55%
Without Discount, Without Age Weighting on DALYs
Argentina 16.50 19.22 116.50%
Chile 35.84 40.00 111.61%
UK 21.47 28.95 134.85%
3.5% Discount Rate Without Age Weighting on DALYs
Argentina 6.95 6.87 98.94%
Chile 15.75 16.39 104.02%
UK 13.20 17.36 131.58%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year.
a Main scenarios for basal analysis (with and without discounting; with or 
without DALY age-weighting). 
DALYs were about 30% higher than QALYs. As an example, 
comparing conjugated pneumococcal vaccine strategy to no 
vaccination in Argentina (scenario without discounting and 
with age weighting) an incremental cost of the intervention of 
$8.5 would make the intervention cost-effective if DALYs are 
used, but cost-ineffective if QALYs are used instead. 
In order to contextualize the findings and gauge the relevance 
of the benefit metric used versus other related choices 
researchers have when performing economic evaluations, 
we evaluated how, with each methodological choice, always 
compared to a common strategy – a scenario with discounted 
QALYs and normative utilities- the benefits can change. A 
summary of the influence of the different choices for both 
disease cases is shown in Table 3, where we show, for each of 
the researchers potential structural/methodological choices 
(columns) how much the baseline benefit differences between 
QALYs and DALYs change.
As we can see, some of the assumptions can influence 
the results similarly or more than the choice of QALYs or 
DALYs as the benefit metric. The largest differences were 
seen comparing to undiscounted results, which is not a 
practice currently recommended. In the case of HPV, the 
inclusion or exclusion of normative utilities was one of the 
most influential parameters, even more influential than the 
choice of the benefit metric (DALY or QALY). In the case 
of Pneumococcal disease, methodological choices showed 
the impact of discounting, and a lower impact of not using 
normative utilities. The other choices (DALYs with or without 
age weight, or using 1-DALY’s disability weight) had an 
inconsistent and heterogeneous influence in the differences.
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More details about the results for the alternative analyses can 
be seen in Appendix 3.
Discussion 
There is no widespread agreement about the choice of the 
measure of health assessment in health economic evaluations, 
and there is also no consensus on using or not combined 
metrics -such as QALYs or DALYs. Germany, for example, 
favors natural units (ie, mm Hg for blood pressure reduction) 
instead of using a combined metric that tries to incorporate 
healthy life and thus morbidity and mortality.19 At the global 
level, key players such as the WHO promotes the use of the 
DALYs, mainly intended for evaluating and comparing 
disease burden across countries.16 In most jurisdictions where 
guidelines for economic evaluations are in place, QALY are 
usually preferred, though there is no consensus or empirical 
recommendations about whether one metric should be 
chosen over another.20,21 We can conceptualize this problem 
as one of structural uncertainty; ie, the assumptions that we 
incorporate into the decision problem, and whether these 
assumptions influence results and decision-making. This 
is only one component of global uncertainty, which also 
includes parameter uncertainty and heterogeneity.22 
In the context of almost no literature empirically addressing 
this issue, we performed an exploratory case study analysis 
using two different models, that had been used in real studies, 
in order to address whether using QALY gained or DALY 
avoided to estimate incremental health benefits could affect 
the final estimation of benefit impact, and consequently the 
cost-effectiveness estimation and the coverage decision when 
adopting widely used decision rules related to the per capita 
GDP per unit of benefit.17 In these two case studies, we did 
not find a systematic pattern regarding the magnitude and 
direction of the differences between DALYs and QALYs. 
These differences were greater in the HPV case, and usually 
significantly smaller in the case of pneumococcal vaccine. 
We found that the decisional impact was higher in the HPV 
than in the pneumococcal case; and results were sensitive 
to discounting as well as age weighting of DALYs. Though 
the latter is no longer recommended for DALYs estimation 
for disease burden, discounting is a standard practice in 
economic evaluation.23-27
Nevertheless, the magnitude of the structural uncertainty due 
to the metric choice was not necessarily greater than that due 
to other assumptions tested, usually based on explicit value 
choices and defended on normative or technical grounds. 
This was especially true in the case of incorporating normative 
utilities, which significantly influence the amount of QALYs 
gained, and thus the differences between QALYs and DALYs. 
The results obtained using normative utilities to calculate 
QALY gains were significantly lower than using a utility of 1 
for the general population.
One possible explanation for the differences observed between 
the case studies analyzed (HPV model vs. pneumococcal 
model) is that the pneumococcal model incorporates 
normative utilities in order to estimate QALY gains in people 
without pneumococcal disease (therefore QALY gains are 
lower than if a utility = 1 is assumed for this healthy people). 
Since normative utilities are not considered in the HPV 
model in order to estimate QALYs gained, differences using 
both metrics could be higher than those observed in the main 
analysis.
Many studies evaluate and criticize the guiding principles of 
DALYs or QALYs, the influence of value choices, methodology, 
usefulness for developing countries, or arguments for their 
standardization. Nevertheless, we found no empirical studies 
that posed our study question. One study in the tuberculosis 
field discusses the pros and cons of using DALYs or QALYs 
but makes no empirical comparison between the methods.28 
Airoldi and Morton29 published a conceptual paper comparing 
the potential benefit of a healthcare intervention measured in 
terms of QALYs vs. DALYs. There are many differences with 
our work, and is thus difficult to extrapolate findings between 
the two. They isolate the effect of framing the problem from 
a health or a disability perspective; did not use age-weighting 
function in calculating DALYs, employed a common 
discounting methodology and the same set of quality of life 
and disability weights. They found that the main difference 
between these measures is the use of life expectancy tables 
to determine the years of life lost component of DALYs. 
Particularly, the use of a death-dependent reference age is 
problematic when the intention is to evaluate the impact 
of life saving interventions. In these cases, some authors 
recommended the use of local period life expectancy tables 
for single-year interventions ‘as long as the changes caused 
by the intervention do not change age-specific and overall life 
expectancies substantially.’30
Using our results for the HPV vaccination model showed 
Table 3. Impact of Scenario Choice on the Estimation of the Magnitude of Benefit Difference, Expressed as the Proportion of Increase or Decrease From 
a Comparator Scenario of Using QALYs With Normative Utilities and Discounting of Both QALYs and DALYs
DALYs 
(No Age Weighting)
DALYs (With Age 
Weighting)
QALYs (No Discount)
QALYs (Non-normative 
Utilities)
1-DALY´s Disability 
Weight
HPV
Argentina 20% 3% 341% 31% 7%
Chile 15% -1% 394% 38% -5%
UK -25% -48% 439% 56% 0%
Pneumococcal
Argentina -1.1% 4.4% 139.0% 6.0% -8.1%
Chile 3.9% -0.2% 122.6% 13.4% -13.2%
UK 24.0% -0.3% 47.6% 17.9% -5.0%
Abbreviations: QALYs, quality-adjusted life years; DALY, disability-adjusted life year; GDP, gross domestic product; HPV, human papilloma virus.
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that DALYs avoided were generally less than QALYs 
gained; just as Airoldi and Morton would predict for a life 
extending intervention. On the other hand, with the model 
that evaluated the introduction of conjugated Pneumococcal 
vaccination, another life extending intervention, we found the 
opposite; that is, DALYs avoided were generally more than 
QALYs gained. 
Some limitations of our study should be noted. Results obtained 
from this exploratory study are difficult to extrapolate to other 
studies. We evaluated only two preventive interventions. As a 
case study, it was built on adapting previously used models, 
and not intended to generalize the findings to wider contexts. 
Also, there has been a recent update of disability weights for 
DALYs.16 Though the agreement between the newer and 
older disability weights set was high (r = 0.70) and would not 
probably alter significantly our results, this is an issue worth 
exploring in future studies. 
Conclusion
Our study, which adapted two previously published models 
to report health benefits both in QALYs and DALYs, shows 
that the magnitude of benefit could be significantly different 
when using one or the other, and these differences did 
not systematically favoured one metric vs. the other. The 
magnitude of this source of uncertainty was similar to that 
of other sources of uncertainty that could lead to different 
decisions about the cost-effectiveness of a health technology. 
As an empirical methodological case study, we consider it 
more as hypothesis generating that an explanatory study. We 
did not find evidence that contradicts current practice of many 
researchers and decision-makers of using and interpreting 
results of QALY or DALY based studies interchangeably 
and thus with the same decision-making threshold. A more 
generalizable analysis using specifically designed models 
could be necessary in order to be able to better understand 
the factors that explain the differences of using each metric. 
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Appendix 1. Model Descriptions: Parameters and Assumptions
 
Death
NoHPVonc
CIN: cervical intraepithelial neoplasia; det: subjects with disease detected through 
screening: same pathways but different probabilities; HPV: human papillomavirus.
det
det
det
Death cancer
CIN 1onc
CIN 2&3
Cancer cured
Persistent CIN 2&3
HPVonc
Cancer
Vaccine
Population 1: 
Present Scenario –
Prevention based on 
Pap screening.
Population 2:
Present Scenario
plus vaccination
Figure A1. HPV Vaccination Model. State Transition Diagram.  
Abbreviation: HPV, human papilloma virus.
Figure A2. Pneumococcal Vaccination Model.
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Figure A3. Cross-Sectional Deterministic Analysis.
 
Table A1. List of States Considered in the HPV Vaccination Model and Utilities Assumptions
State Description and Utilities
No oncogenic HPV infection
Healthy woman. No disutility was assumed. A QALY weight of 1 was used in order to estimate total QALYs. No additional 
YLDs by this condition were assumed.
Oncogenic HPV infection Asymptomatic condition. A same utility/disutility that a healthy woman was assumed.
CIN 1 undetected Asymptomatic condition. A same utility/disutility that a healthy woman was assumed.
CIN 1 detected Country specific QALY weights were estimated. Models were reprogrammed in order to measure YLDs by this condition.
CIN 2 & 3 undetected Asymptomatic condition. A same utility/disutility that a healthy woman was assumed.
CIN 2 & 3 detected Country specific QALY weights were estimated. Models were reprogrammed in order to measure YLDs by this condition.
Persistent CIN 2 & 3 undetected Asymptomatic condition. A same utility/disutility that a healthy woman was assumed.
Persistent CIN 2 & 3 detected A same utility/disutility that the CIN 2 & 3 detected state was assumed.
Cancer Country specific QALY weights were estimated. Models were reprogrammed in order to measure YLDs by this condition.
Cancer cured Country specific QALY weights were estimated. Models were reprogrammed in order to measure YLDs by this condition.
Overall death A QALY weight of zero was use for this state. Models were reprogrammed in order to measure YLLs by premature death.
Death by cervical cancer A QALY weight of zero was use for this state. Models were reprogrammed in order to measure YLLs by premature death.
Abbreviations: QALY, quality-adjusted life year; HPV, human papilloma virus; YLD, years of life with disability; YLL, years of life lost; CIN, cervical intraepithelial 
neoplasia.
Table A2. Health Conditions Considered in the Pneumococcal Vaccination Modela
Disease Outcome Duration (wk)
Short-term disability associated with acute disease (applied to current year, not discounted)
Meningitis (inpatient) 2.3143
Bacteraemia (inpatient) 1.7714
Pneumonia (inpatient) 1.5806
Pneumonia (outpatient) 0.7903
AOM (outpatient) 0.1429
AOM hospitalized myringotomy 0.1429
Long-term disability associated with sequelae (applied to lifetime, discounted)
Neurological sequelae from meningitis More than 1 year
Hearing Loss from meningitis More than 1 year
Hearing Loss from AOM More than 1 year
Abbreviation: AOM, acute otitis media.
a Values correspond to the mean duration of disability for mentioned conditions according to the original health economic evaluation of pneumococcal 
vaccination for the United Kingdom.
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Appendix 2. DALYs Estimation Methods
Appendix 3. Analyses of Alternative Scenarios 
Both models were reprogrammed in order to estimate DALYs. 
For calculating DALYs we followed a standard methodology 
described to estimate both YLDs and YLLs.14 For YLDs, we 
used the following equation:
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parameter of the age weighting function (0.04); LE = standard 
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In all cases, a β value of 0.04 was used, according to Fox-Rushby14. K and r values can be 
set as independent parameters in mod ls.    
Two parameters are especially important in order to estimate YLDs: duration of the 
condition, and disability weight associated. For the HPV vaccination model, duration of each 
health state by age of onset for women with different participation on screening program (regular, 
irregular or no participation) was measured from the same in order to not include systematic  
differences with QALYs estimation. For DALYs estimations, mean duration data was linked with 
the estimation cells, so this information is automatically taken from the performance of the model 
and was not considered as an input.  
For the Pneumococcal vaccination model duration of conditions that last less of 1 year 
was considered the same that the duration in the model, and were obtained from the health 
economic evaluation for UK. In the other hand, conditions that last more than 1 year (auditive 
and neurologic sequelae) are assumed not to increase the probability of death and not to be 
reversible. So duration is equal to life expectancy (in each country) at age of onset (same 
assumption that in the health economic evaluation for UK). The same assumption was used on 
QALY estimation.  
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In all cases, a β value of 0.04 was used, according to Fox-
Rushby.14 K and r values can be set as independent parameters 
in models. 
Two parameters are especially important in order to estimate 
YLDs: duration of the condition, and disability weight 
associated. For the HPV vaccination model, duration of 
each health state by age of onset for women with different 
participation on screening program (regular, irregular or no 
participation) was measured from the same in order to not 
include systematic differences with QALYs estimation. For 
DALYs estimations, mean duration data was linked with the 
estimation cells, so this information is automatically taken 
from the performance of the model and was not considered 
as an input. 
For the pneumococcal vaccination model duration of 
conditions that last less of 1 year was considered the same 
that the duration in the model, and were obtained from the 
health economic evaluation for the United Kingdom. In the 
other hand, conditions that last more than 1 year (auditive 
and neurologic sequelae) are assumed not to increase the 
probability of death and not to be reversible. So duration 
is equal to life expectancy (in each country) at age of onset 
(same assumption that in the health economic evaluation for 
the United Kingdom). The same assumption was used on 
QALY estimation. 
Standard methodology for DALYs estimation requires using 
the same disability weight for each country. The GBoD project 
covers a wider range of conditions, and disability weights 
(2004) provided has been widely used.13
As some of the weights are not included in the GBoD project, 
disability weights for stages of the HPV vaccination model 
were obtained using the same methodology described in 
the Dutch study, involving the estimation of weights for 175 
disease stages, sequelae and severity levels. This method 
allows to estimate disability weights from EQ-5D descriptive 
states by m an f a regression model.16 EQ5D descriptive 
states were obtained from the survey mentioned previously 
and already published.9
In order to address the potential i fluence of local EQ-5D 
social values/tariffs in the base case differe ces we replaced 
the values for each country and using 1-disability weight from 
GBD project as the quality of life weight. In that way we used 
a same coefficient in all countries in order to estimate QALYs 
gained, which is the complementary value of disability weights 
used for DALYs estimation. This change has a different effect 
on incremental utility differences using QALYs gained and 
DALYs avoided: an increase on DALY/QALY percentage 
ratio of about 6% in Argentina, a decrease between 3% and 
5% (without and with discount respectively) in Chile, and a 
negligible change in the United Kingdom. This makes more 
similar the differences observed in Argentina and Chile, 
eaning that differences between these countries could be 
explained at least in part by using different EQ-5D tariffs. 
Table A4 shows the new QALYs gained and DALYs avoided 
estimations and Figure A4 shows the effect on threshold 
analysis which was of the same magnitude as mentioned 
previously. Differences between QALYs gained and DALYs 
avoided were again lower when no discount (in both QALYs 
and DALYs estimations) and no age weighting (in DALYs 
estimation) were applied. 
Finally, we incorporated normative utilities into the HPV 
vaccination models. This change decreased the expected 
QALYs gained, increasing DALY/QALY percentage ratio in 
all countries (see Table A5). This was translated in change 
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in most of the cases, with thresholds analysis estimation for 
DALYs higher than threshold analysis estimations for QALYs 
(see Figure A5).
Pneumococcal Vaccine Additional Scenarios
Similarly to the HPV model, different alternative scenarios 
were evaluated (EQ-5D weights replaced by 1-disability 
weight, in the alternative analysis in order to reduce between 
countries variability in QALYs gained estimations. New 
QALYs gained estimations produced a difference in the 
DALY/QALY percentage ratio in a range of -1% to +16% 
comparing against the base cases analysis. Table A6 shows 
new estimations using 1-disability weights as EQ-5D QALY 
weights. 
Since these changes were small, lower differences on threshold 
analysis using both QALYs gained and DALYs avoided for 
Chile and UK were still found when 3.5% discount rate and 
age weighting were used (see Figure A6). For Argentina, the 
lowest difference was found when 3.5% discount rate without 
age weighting analysis was performed. 
Several alternative analyses were carried-out: excluding 
Table A3. Normative Utilities for Each Country
Age Group Argentina Chile UK
< 16 years 0.95 0.88 0.91
16-24 years 0.95 0.88 0.91
25-34 years 0.94 0.87 0.91
35-44 years 0.92 0.84 0.88
45-54 years 0.90 0.79 0.85
55-64 years 0.87 0.70 0.79
65-74 years 0.83 0.66 0.78
≥ 75 years 0.76 0.59 0.73
Table A4. Incremental Utility Comparing HPV Vaccination Against no 
Vaccination (Per 100 000 Women)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Without Discount, With Age Weighting 
Argentina 14 693.51 11 377.14 77.43%
Chile 9702.73 6969.72 71.83%
UK 9195.49 5484.66 59.65%
3.5% Discount Rate With Age Weighting
Argentina 2626.00 1843.39 70.20%
Chile 1586.17 1142.28 72.01%
UK 1860.70 796.37 42.80%
Without Discount, Without Age Weighting
Argentina 14 693.51 14 965.23 101.85%
Chile 9702.73 9321.46 96.07%
UK 9195.49 7431.34 80.82%
3.5% Discount Rate Without Age Weighting
Argentina 2626.00 2211.29 84.21%
Chile 1586.17 1357.41 85.58%
UK 1860.70 1025.83 55.13%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year; HPV, human papilloma virus.
a Alternative analysis QALY coefficients = 1-disability weight.
Table A5. Incremental Utility Comparing HPV Vaccination Against no 
Vaccination (Per 100 000 Women)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Without Discount, With Age Weighting 
Argentina 9312.50 11 377.14 122.17%
Chile 6500.03 6969.72 107.23%
UK 5788.85 5484.66 94.75%
3.5% Discount Rate With Age Weighting
Argentina 1778.19 1843.39 103.67%
Chile 1149.87 1142.28 99.34%
UK 1286.60 796.37 61.90%
Without Discount, Without Age Weighting
Argentina 9312.50 14 965.23 160.70%
Chile 6500.03 9321.46 143.41%
UK 5788.85 7431.34 128.37%
3.5% Discount Rate Without Age Weighting
Argentina 1778.19 2211.29 124.36%
Chile 1149.87 1357.41 118.05%
UK 1286.60 1025.83 79.73%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year; HPV, human papilloma virus.
a Alternative analysis including normative utilities.
normative utilities from all models, using local life 
expectancies to DALYs estimations, using a same population 
structure and excluding herd protection from the analysis. 
As expected in the alternative analysis using normative 
utilities, QALYs gained increased, reducing the DALY/QALY 
percentage ratio in all countries (see Table A7). Using of local 
life expectancies in each country produced a DALYs avoided 
estimations reduction between -8% to -1% (see Table A8). 
Using the same population structure to the other countries 
produced a change on DALY/QALY percentage ratio ranged 
from -1% to +11% (see Table A9). Finally, the without herd 
immunity analysis produced the bigger differences between 
countries related to changes on the DALY/QALY percentage 
ratio. Meanwhile negligible changes were observed for 
Argentina, DALY/QALY percentage ratio was reduced for 
more than 50% in some cases for UK (see Table A9). As 
exclusion of herd immunity of models reduced the effect 
of vaccination only to less of 10 years old populations, age 
range used for economic evaluations could explain (at least 
in part) differences between DALYs and QALYs. Decision 
impact analyses for these alternative scenarios are shown in 
the Appendix, Figures A7 to A12.
A special analysis on two selected variables related to 
acute otitis media (AOM) was performed since variables 
related to this condition showed a higher impact on final 
cost-effectiveness ratio in the sensitivity analysis of the 
original models. In this sense, proportion of Streptococcus 
pneumoniae in AOM and AOM incidence were increased in 
a 20% in each country. Changes in QALYs gained and DALYs 
avoided estimations, as well as DALY/QALY percentage ratio 
and threshold analyses were negligible (lower of 1% for all 
countries), as compared against the base case analysis (see 
Tables A10 and A11).
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Table A6. Incremental Utility Comparing Conjugated Pneumococcal 
Vaccination Against no Vaccination (Per 100 000 subjects)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Synflorix vs. no Vaccination
Without Discount, With Age Weighting 
Argentina 16.03 20.27 126.44%
Chile 32.24 40.10 124.36%
UK 20.48 22.29 108.85%
3.5%  Discount Rate With Age Weighting
Argentina 6.39 7.25 113.46%
Chile 15.75 15.72 99.79%
UK 13.27 13.14 99.02%
Without Discount, Without Age Weighting
Argentina 16.03 19.22 119.90%
Chile 32.24 40.00 124.05%
UK 20.48 28.95 141.36%
3.5% Discount Rate Without Age Weighting
Argentina 6.39 6.87 107.55%
Chile 13.58 16.39 120.64%
UK 12.32 17.36 140.89%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year.
a Alternative analysis QALY coefficients = 1-disability weight.
Table A7.  Incremental Utility Comparing Synflorix® Vaccination Against no 
Vaccination (Per 100 000 Women)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Synflorix vs. no Vaccination
Without Discount, With Age Weighting 
Argentina 18.13 20.27 111.83%
Chile 41.54 40.10 96.52%
UK 26.60 22.29 83.81%
3.5%  Discount Rate With Age Weighting
Argentina 7.36 7.25 98.55%
Chile 17.95 15.72 87.57%
UK 16.31 13.14 80.55%
Without Discount, Without Age Weighting
Argentina 18.13 19.22 106.05%
Chile 41.54 40.00 96.29%
UK 26.60 28.95 108.85%
3.5% Discount Rate Without Age Weighting
Argentina 7.36 6.87 93.42%
Chile 17.95 16.39 91.28%
UK 12.32 17.36 140.89%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year.
a Alternative analysis without normative utilities.
Table A8.  Incremental Utility Comparing Synflorix® Vaccination Against no 
Vaccination (Per 100 000 Women)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Synflorix vs. no Vaccination
Without Discount, With Age Weighting 
Argentina 16.50 19.38 117.46%
Chile 35.84 39.31 109.68%
UK 21.47 21.93 102.15%
3.5%  Discount Rate With Age Weighting
Argentina 6.95 7.19 103.46%
Chile 15.75 15.57 98.84%
UK 13.20 13.05 98.88%
Without Discount, Without Age Weighting
Argentina 16.50 17.66 107.05%
Chile 35.84 38.48 107.37%
UK 21.47 28.24 131.52%
3.5% Discount Rate Without Age Weighting
Argentina 6.95 6.76 97.31%
Chile 15.75 16.07 101.99%
UK 13.20 17.20 130.34%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year.
a Alternative analysis using local life expectancies.
Table A9.  Incremental Utility Comparing Synflorix® Vaccination Against no 
Vaccination (Per 100 000 Women)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Synflorix vs. no Vaccination
Without Discount, With Age Weighting 
Argentina 11.48 14.04 122.30%
Chile 31.18 34.66 111.17%
UK 21.47 22.29 103.83%
3.5%  Discount Rate With Age Weighting
Argentina 4.89 5.06 103.59%
Chile 14.57 14.60 100.23%
UK 13.20 13.14 99.55%
Without Discount, Without Age Weighting
Argentina 11.48 13.38 116.61%
Chile 31.18 36.74 117.82%
UK 21.47 28.95 134.85%
3.5% Discount Rate Without Age Weighting
Argentina 4.89 4.86 99.37%
Chile 14.57 16.82 115.49%
UK 13.20 17.36 131.58%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year.
a Alternative analysis using UK population structure.
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Table A10. Incremental Utility Comparing Synflorix® Vaccination Against 
no Vaccination (Per 100 000 Women)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Synflorix vs. no Vaccination
Without Discount, With Age Weighting 
Argentina 16.56 20.27 122.40%
Chile 35.89 40.10 111.71%
UK 21.54 22.29 103.49%
3.5%  Discount Rate With Age Weighting
Argentina 7.01 7.25 103.47%
Chile 15.81 15.72 99.43%
UK 13.27 13.14 99.02%
Without Discount, Without Age Weighting
Argentina 16.56 19.23 116.11%
Chile 35.89 40.00 111.45%
UK 21.54 28.96 134.43%
3.5% Discount Rate Without Age Weighting
Argentina 7.01 6.88 98.17%
Chile 15.81 16.39 103.67%
UK 13.27 17.37 130.91%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year.
a Alternative analysis AOM Streptococcus pneumoniae prevalence +20%.
Table A11. Incremental Utility Comparing Synflorix® Vaccination Against 
no Vaccination (Per 100 000 Women)a
Country QALYs Gained DALYs Avoided DALY/QALY 
Percentage Ratio
Synflorix vs. no Vaccination
Without Discount, With Age Weighting 
Argentina 16.59 20.27 122.17%
Chile 35.93 40.10 111.60%
UK 21.61 22.30 103.17%
3.5%  Discount Rate With Age Weighting
Argentina 7.04 7.26 103.01%
Chile 15.85 15.72 99.21%
UK 13.34 13.14 98.53%
Without Discount, Without Age Weighting
Argentina 16.59 19.24 115.91%
Chile 35.93 40.01 111.34%
UK 21.61 28.96 134.04%
3.5% Discount Rate Without Age Weighting
Argentina 7.04 6.89 97.78%
Chile 15.85 16.39 103.46%
UK 13.34 17.38 130.29%
Abbreviations: QALY, quality-adjusted life year; DALY, disability-adjusted life 
year.
a Alternative analysis AOM incidence +20%.
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Appendix Figure 1. HPV Vaccination Strategy: mean incremental costs where decisions 
using 1 or 3 GDP thresholds change using QALYs or DALYs for Argentina, Chile and United 
Kingdom (UK). Alternative analysis QALY coefficients= 1-disability weight. 
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Figure A4. HPV Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or DALYs 
for Argentina, Chile and the United Kingdom. Alternative analysis QALY coefficients= 1-disability weight.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
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Appendix Figure 2. HPV Vaccination Strategy: Mean Incremental Costs Where Decisions 
Using 1 or 3 GDP Thresholds Change Using QALYs or DALYs  for Argentina, Chile and the 
United Kingdom.  Alternative analysis including normative utilities. 
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Figure A5. HPV Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or DALYs 
for Argentina, Chile and the United Kingdom.  Alternative analysis including normative utilities.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
Figure A6. Conjugated Pneumococcal Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change 
Using QALYs or DALYs for Argentina, Chile and the United Kingdom. Alternative analysis without normative utilities.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
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Appendix Figure 3. Conjugated Pneumococcal Vaccination Strategy: mean incremental costs 
where decisions using 1 or 3 GDP thresholds change using QALYs or DALYs for Argentina, 
Chile and United Kingdom (UK). Alternative analysis without normative utilities. 
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Figure A7. Synflorix® Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or 
DALYs  for Argentina, Chile and the United Kingdom. Alternative analysis using local life expectancies for DALYs estimations.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
Figure A8. Synflorix® Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or 
DALYs  for Argentina, Chile and the United Kingdom. Alternative analysis using population distribution of the United Kingdom.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
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Appendix Figure 4. Synflorix® Vaccination Strategy: mean incremental costs where 
decisions using 1 or 3 GDP thresholds change using QALYs or DALYs  for Argentina, Chile 
and United Kingdom (UK). Alternative analysis using local life expectancies for DALYs 
estimations. 
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Appendix Figure 5. Synflorix® Vaccination Strategy: mean incremental costs where 
decisions using 1 or 3 GDP thresholds change using QALYs or DALYs  for Argentina, Chile 
and United Kingdom (UK). Alternative analysis using population distribution of UK. 
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Appendix Figure 6. Synflorix® Vaccination Strategy: mean incremental costs where 
decisions using 1 or 3 GDP thresholds change using QALYs or DALYs  for Argentina, Chile 
and United Kingdom (UK). Alternative analysis QALY coefficients = 1-disability weight. 
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Figure A9. Synflorix® Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or 
DALYs  for Argentina, Chile and the United Kingdom. Alternative analysis QALY coefficients = 1-disability weight.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
Figure A10. Synflorix® Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or 
DALYs for Argentina, Chile and the United Kingdom). Alternative analysis excluding herd immunity.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus.
46 
 
Appendix Figure 7. Synflorix® Vaccination Strategy: mean incremental costs where 
decisions using 1 or 3 GDP thresholds change using QALYs or DALYs  for Argentina, Chile 
and United Kingdom (UK). Alternative analysis excluding herd immunity. 
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Figure A11. Synflorix® Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or 
DALYs  for Argentina, Chile and the United Kingdom. Alternative analysis AOM Streptococcus pneumoniae prevalence +20%.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus; 
AOM, acute otitis media.
Figure A12. Synflorix® Vaccination Strategy: Mean Incremental Costs Where Decisions Using 1 or 3 GDP Thresholds Change Using QALYs or 
DALYs  for Argentina, Chile and the United Kingdom. Alternative analysis AOM incidence +20%.
Abbreviations: QALYs, quality-adjusted life years; DALYs, disability-adjusted life years; GDP, gross domestic product; HPV, human papilloma virus; 
AOM, acute otitis media.
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Appendix Figure 8. Synflorix® Vaccination Strategy: mean incremental costs where 
decisions using 1 or 3 GDP thresholds change using QALYs or DALYs  for Argentina, Chile 
and United Kingdom (UK). Alternative analysis AOM Streptococcus pneumoniae 
prevalence +20%. 
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Appendix Figure 8. Synflorix® Vaccination Strategy: me n incremental costs where 
decisions using 1 or 3 GDP thresholds change u ing QALYs or DALYs  for rgentina, Chile 
and United Kingdom (UK). Alternative analysis AOM Streptococcus pneumoniae 
prevalence +20%. 
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Appendix Figure 9. Synflorix® Vaccination Strategy: mean incremental costs where 
decisions using 1 or 3 GDP thresholds change using QALYs or DALYs  for Argentina, Chile 
and United Kingdom (UK). Alternative analysis AOM incidence +20%. 
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